Ocuphire Pharma Inc. will prioritize the development of Nyxol eye drops for three indications following positive topline results from two phase 2 studies, the company announced.
Indications are moderate-to-severe night vision disturbance (NVD), reversal of mydriasis and presbyopia, according to a company press release.
In the multi-center, randomized, double-masked, placebo-controlled MIRA-1 study, phentolamine mesylate ophthalmic solution 1% (Nyxol) reduced pharmacologically induced mydriasis 2 hours after treatment and reduced pupil diameter sooner than placebo.
In the ORION-1 multicenter,
Uncategorized